|Simi Valley, CA- June 10, 2013- VDI Laboratory announced the release of VDI-TKfeline+, the third dual-biomarker blood panel for the detection and monitoring of cancer in companion animals. The original feline test, utilizing a single proliferative biomarker, was released in April, 2011 and has been widely accepted as an aid for the differentiation of feline intestinal lymphoma from inflammatory bowel disease (IBD) in cats.
The experience gained in developing the dual-biomarker canine cancer blood test enabled the development of a similar system for the feline cancer test. The integration of the inflammatory biomarker haptoglobin with the proliferative marker thymidine kinase, improves test performance by allowing VDI-TKfeline+ to not only better detect lymphoma, but also rule-out lymphoma or IBD as a possible diagnosis.
"We completed fundamental modifications to the feline cancer blood test, enhancing overall test performance," says Randy Ringold, President of VDI. "Improvements to the thymidine Kinase assay, the addition of haptoglobin, and the implementation of the Neoplasia Index, give veterinarians more tools to diagnose and treat challenging diseases in cats".
These improvements make VDI-TKfeline+ the third dual-biomarker panel for cancer management from VDI Laboratory. Along with VDI-TKcanine+ and INCaSe health and cancer screen, VDI continually looks to provide veterinarians with innovations to accurately and cost effectively manage disease in companion animals.
About VDI Laboratory
VDI Laboratory (VDI) is a specialty diagnostics company that provides veterinary reference laboratory services and in-house diagnostic products. VDI is dedicated to the research and development of innovative biomarkers to assist veterinarians in the diagnostic workup of companion animals. VDI continues to pursue new biomarkers in a variety of disease states and other challenging situations facing the veterinarian. Stay informed by visiting VDI on Facebook or at VDIlab.com.